期刊文献+

高分级脑胶质瘤术后复发的相关影响因素分析 被引量:2

INFLUENCING FACTORS FOR POSTOPERATIVE RECURRENCE OF HIGH-GRADE GLIOMA
下载PDF
导出
摘要 目的探讨影响高分级脑胶质瘤术后复发的相关因素,为临床对脑胶质瘤预后判断提供帮助。方法回顾性分析我院神经外科150例高分级脑胶质瘤病人的临床资料,采用SPSS软件分析各因素与肿瘤复发的关系。结果单因素分析结果显示,年龄(χ~2=21.74,P<0.05)、术前抽搐(χ~2=9.76,P<0.05)、肿瘤病理分级(χ~2=7.64,P<0.05)、术后放疗(χ~2=21.79,P<0.05)、术后化疗(χ~2=31.52,P<0.05)以及肿瘤分子标志物IDH1突变状态(χ~2=33.79,P<0.05)与高分级脑胶质瘤病人术后复发有关;多元Logistic逐步回归分析结果显示,年龄(OR=4.29,95%CI=2.05~8.97,P<0.05)、术后放疗(OR=2.81,95%CI=1.24~6.37,P<0.05)、术后化疗(OR=7.69,95%CI=3.04~19.44,P<0.05)、IDH1突变状态(OR=5.51,95%CI=2.64~11.49,P<0.05)是高分级脑胶质瘤病人术后复发的独立影响因素。结论年龄>50岁、术后未行放化疗、IDH1野生型是高分级脑胶质瘤病人术后复发的危险因素。 Objective To investigate the influencing factors for postoperative recurrence of high-grade glioma,and to provide some help for prognostic evaluation of glioma. Methods A retrospective analysis was performed for the clinical data of150 patients with high-grade glioma who were treated in Department of Neurosurgery in our hospital.SPSS software was used to analyze the association between various factors and tumor recurrence. Results The univariate analysis showed that age(χ~2=21.74,P0.05),preoperative convulsion(χ~2=9.76,P0.05),tumor grade(χ~2=7.64,P0.05),postoperative radiotherapy(χ~2=21.79,P0.05),postoperative chemotherapy(χ~2=31.52,P0.05),and IDH1 mutation status(χ~2=33.79,P0.05)were associated with postoperative recurrence of high-grade glioma.The results of the multivariate logistic stepwise regression analysis showed that age(odds ratio(OR)=4.29,95% confidence interval(CI)=2.05-8.97,P0.05),postoperative radiotherapy(OR=2.81,95%CI=1.24-6.37,P 0.05),postoperative chemotherapy(OR=7.69,95%CI=3.04-19.44,P 0.05),and IDH1 mutation status(OR=5.51,95%CI=2.64-11.49,P0.05)were independent influencing factors for postoperative recurrence in patients with high-grade glioma. Conclusion Age50 years,absence of radiochemotherapy after surgery,and wildtype IDH1 are risk factors for postoperative recurrence in patients with high-grade glioma.
出处 《齐鲁医学杂志》 2017年第4期379-381,385,共4页 Medical Journal of Qilu
基金 国家自然科学基金资助项目(81472812)
关键词 神经胶质瘤 复发 预后 影响因素分析 glioma recurrence prognosis root cause analysis
  • 相关文献

参考文献3

二级参考文献33

  • 1牟永告,陈明振,陈忠平,周旺宁,张湘衡,赛克.脑胶质瘤的显微手术治疗——附183例报告[J].癌症,2004,23(11):1317-1321. 被引量:3
  • 2Cavaliere R, Wen PY, Schiff D. Novel therapies for malignant gliomas. Neurol Clin, 2007, 25 : 1141-1171.
  • 3Ma J, Murphy M, O' Dwyer PJ, et al. Biochemical changes associated with a muhidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Biochem Pharmacol, 2002, 63 : 1219-1228.
  • 4Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol, 2002, 20:2388-2399.
  • 5Middleton MR, Thatcher N, McMurry TB, et al. Effect of O^6-(4- bromothenyl) guanine on different temozolomide schedules in a human melanoma xenograft model. Int J Cancer, 2002, 100:615- 617.
  • 6Broniscer A, Gururangan S, MacDonald TJ, et al. Phase I trial of single-dose temozolomide and continuous administration of O^6- benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Clin Cancer Res, 2007, 13:6712-6718.
  • 7Quinn JA, Desjardins A, Weingart J, et al. Phase I trial of temozolomide plus O^6-benzylguartine for patients with recurrent or progressive malignant glioma. J Clin Oncol, 2005, 23:7178-7187.
  • 8Rosati SF, Williams RF, Nunnally LC, et al. IFN-beta sensitizes neuroblastoma to the antitumor activity of temozolomide by modulating O^6-methylguanine DNA methyltransferase expression. Mol Cancer Ther, 2008, 7:3852-3858.
  • 9Ranson M, Middleton MR, Bridgewater J, et al. Lomeguatrib, a potent inhibitor of O^6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res, 2006, 12 : 1577-1584.
  • 10Turriziani M, Caporaso P, Bonmassar L, et al. O^6-(4-bromothenyl) guanine (PaTrin-2), a novel inhibitor of O^6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro. Pharmacol Res, 2006.53:317-323.

共引文献21

同被引文献26

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部